Highlights

  • EchoIQ has entered a proposed strategic Investment and commercial Partnership arrangement with Pro Medicus.
  • The company is evaluating its platform through a Mayo Clinic cardio-oncology research collaboration.
  • EchoIQ completed an institutional Placement of about A$110 million during the June quarter.
  • EchoSolv AS processed more than 10,200 echocardiograms during the quarter.

Two agreements struck weeks apart have changed how the market views EchoIQ (ASX:EIQ). In its June-quarter report, lodged on 27 July 2026, the cardiac-AI developer confirmed a binding heads of agreement with imaging software group Pro Medicus (ASX:PME) covering a proposed strategic investment of up to A$20 million and a US commercial partnership, alongside a research collaboration with the Mayo Clinic evaluating its platform in cardio-oncology. The same report disclosed a completed institutional placement of roughly A$110 million. EchoIQ finished the quarter with A$8.7 million of cash and nil receipts from customers, so the raise changes its funding position.

Company and market context

EchoIQ is a Sydney-headquartered developer of artificial-intelligence decision support for cardiology. Its lead product, EchoSolv AS, analyses measurements taken during a routine echocardiogram to flag patients at risk of severe aortic stenosis, a valve disease that is frequently under-diagnosed. The company states that the system works from measurement data rather than image analysis, allowing it to operate within existing reporting workflows. EchoSolv AS is cleared by the US Food and Drug Administration and marketed in the United States only. A second product, EchoSolv HF, extends the same approach to heart failure and is intended to broaden the platform’s applications. It has been submitted to the FDA and remains under review.

Commercially, EchoIQ (ASX:EIQ) is an early-stage US software Business rather than an Australian healthcare operator. The company announced deployment of EchoSolv AS into the Mount Sinai Health System on 30 April 2026. The business remains focused on converting clinical adoption into commercial contracts.

The latest catalyst

EchoIQ said Pro Medicus will make an initial A$10 million investment through secured convertible notes, with an option to invest a further A$10 million subject to FDA clearance of EchoSolv HF. The commercial element provides a pathway for Pro Medicus to market and distribute the EchoSolv suite through its network of US health systems, subject to regulatory clearance. Definitive documentation was still being finalised at the time of the report.

The Mayo Clinic collaboration, announced on 12 June 2026, is a research study evaluating cardiac risk stratification in patients receiving cancer therapy. Results are anticipated in the first half of calendar 2027.

Also disclosed after quarter-end was an exclusive data licence with Advara HeartCare covering 500,000 to 1,000,000 deidentified echocardiography studies. On market access, the company pointed to a US Centres for Medicare and Medicaid Services proposal under the calendar-2027 outpatient payment rule that would assign eligible software-as-a-medical-service to New Technology payment categories, and to the inclusion of heart failure in CMS's mandatory Ambulatory Specialty Model. Two sales programmes also launched: EchoSolv VIEW, allowing prospects to test performance against their own historical data, and EchoSolv SHADOW, a non-disruptive deployment alongside existing workflows.

What the numbers show

The Appendix 4C shows receipts from customers of nil for the June quarter. Net operating cash outflow was A$2.733 million for the quarter and A$10.565 million for the financial year to date. Cash stood at A$8.712 million at 30 June 2026, down from A$11.14 million at 31 March 2026. Staff costs of A$1.739 million and administration of A$1.013 million represented the largest spending categories.

Usage remains a key operating metric. EchoSolv AS processed more than 10,200 echocardiograms during the quarter, a 20 per cent increase on the March quarter and a rise of more than 400 per cent year on year, taking cumulative 2026 processing beyond 20,000 scans. The US pipeline covers more than 70 hospitals across seven sales stages, including three enterprise proposals that collectively represent more than 300 US hospitals. No contract values, annual Recurring Revenue or per-scan pricing were disclosed.

EchoIQ reported revenue of about A$0.1 million and a net loss of A$13.26 million in FY25; on a trailing twelve-month basis to 31 December 2025 the loss was A$15.71 million.

Why investors are watching

The investment case around EchoIQ (ASX:EIQ) centres on the combination of regulatory clearance, healthcare partnerships, clinical validation and commercial expansion potential. Investors are monitoring the Pro Medicus arrangement, Mayo Clinic collaboration, Advara HeartCare data access and the progress of EchoSolv HF through the FDA review process.

The company has also increased its financial capacity following the A$110 million institutional placement, providing additional funding to support sales activity, product development and commercial initiatives. The key focus remains converting platform adoption and healthcare engagement into recurring revenue.

What could drive the next move

The FDA decision on EchoSolv HF is the clearest upcoming milestone, as it is linked to the second A$10 million Pro Medicus investment Tranche and the proposed distribution pathway. Completion of definitive Pro Medicus documentation is another key step. Conversion of enterprise proposals into signed customer agreements would provide further visibility on revenue generation. CMS developments relating to software-as-a-medical-service payment categories remain another factor, while full-year accounts are due under ASX rules by the end of September 2026.

Risks

The gap between valuation expectations and current revenue remains a key risk. EchoIQ has reported nil quarterly customer receipts, and delays or setbacks in FDA review of EchoSolv HF could affect commercial plans. The Pro Medicus arrangement remains subject to definitive documentation, while the distribution pathway depends on regulatory clearance.

Reimbursement remains under development rather than established policy. Enterprise healthcare sales cycles can be lengthy, and pipeline figures represent potential opportunities rather than contracted revenue. The business is also concentrated in the US market and focused on cardiac applications until additional products achieve clearance.

Outlook

EchoIQ enters the second half of calendar 2026 with additional funding, a proposed distribution relationship and increasing EchoSolv AS usage. The next stage will focus on whether processing growth and hospital pipeline activity translate into contracted recurring revenue. Key milestones include the FDA review outcome for EchoSolv HF, Pro Medicus agreement completion, commercial adoption across US health systems and progress from the Mayo Clinic research collaboration. These developments will determine the pace of commercialisation for the medical-AI platform.